Cite
HARVARD Citation
Konstantinopoulos, P. et al. (2019). Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet oncology. 20 (4), pp. 570-580. [Online].